


Amendments to the Claims

1. (Currently Amended) A benzisothiazole-3(2H)-one compound of formula (I)



(I)

wherein;

R₁ is the group (C₅-C₇)alkyl, (C₄-C₁₂)haloalkyl, -CF₃, allyl, (C₄-C₁₂)alkenyl, (C₄-C₁₂)alkylheterocyclic radical, (C₂-C₄), and (C₂-C₄)alkylaryl, or aryl; wherein the aryl or heterocyclic group is optionally substituted and the benzyl is substituted with 1 to 3 groups independently selected from (C₁-C₁₂)alkyl, (C₂-C₁₂)alkenyl, (C₁-C₁₂)alkoxy, (C₁-C₂)alkylheterocyclic, and (C₁-C₁₂)haloalkyl;

R₂ is hydrogen;

R₃, R₄, R₅, and R₆, are each independently selected from hydrogen, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, -O-(C₁-C₃ alkyl), COOH, C(O)(C₁-C₃ alkyl), C(O)O(C₁-C₃ alkyl), -CF₃, and halo (C₂-C₁₂)alkyl, (C₂-C₁₂)haloalkyl, (C₂-C₁₂)alkoxyalkyl, (C₂-C₁₂)thioalkyl, hydroxy, (C₂-C₁₂)alkenyl, (C₂-C₁₂)alkynyl, (C₂-C₁₂)alkylaryl, (C₂-C₁₂)alkylheterocyclic, (C(O)C₄-C₆alkyl, C(O)OC₄-C₆alkyl, phenyl or aryl; wherein each of alkyl, alkenyl, phenyl or aryl groups may be optionally substituted with one to three substituents selected from halo, amine, halo, C₄-C₆alkyl, (C₂-C₆)alkenyl, (C₄-C₆)haloalkyl; or a pharmaceutically acceptable salt, solvate or isomer thereof.

2. (Canceled)


3. (Currently Amended) A compound according to Claim 1 wherein R₁ is allyl(C₅-C₇)alkyl, (C₄-C₆)alkenyl, -O-(C₄-C₃-alkyl), (C₃-C₄)alkylcycloalkyl, or -CF₃, or aryl.

4. (Currently Amended) A compound according to Claim 1 wherein R₁ is benzyl substituted with 2 substituents selected from (C₁-C₆)alkyl, (C₂-C₄)alkenyl, -O-(C₄-C₃-alkyl), (C₁-C₄)alkylethoxyalkyl, and -CF₃.

5. (Cancelled)

6. (Currently Amended) The compound of Claim 1 wherein R₅ is the group represented by COOH, C(O)(C₄-C₃-alkyl), C(O)O(C₄-C₃-alkyl), chloro, bromo or CF₃.




7. (Currently Amended) A compound of formula (I)




wherein R₄ through R₆ are selected to provide a compound selected from the group consisting of:
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid allylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid pentylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid hexylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid (5-methyl-hexyl)-amide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid cyclohexylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-methyl-benzylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 3-methyl-benzylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 4-methyl-benzylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-ethyl-6-methyl-benzylamide;
 3-Oxo-3H-benzo[d]isothiazole-2-carboxylic acid 2-isopropyl-6-methyl-benzylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid phenethylamide;
3-Oxo 3*H*-benzo[*d*]isothiazole-2-carboxylic acid (2-thiophen-2-yl ethyl) amide;
3-Oxo 3*H*-benzo[*d*]isothiazole-2-carboxylic acid (3-phenyl propyl) amide;
3-Oxo 3*H*-benzo[*d*]isothiazole-2-carboxylic acid (4-phenyl butyl) amide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (4-cyclohexyl-butyl)-amide;
5-Methyl 3-oxo 3*H*-benzo[*d*]isothiazole-2-carboxylic acid butylamide;
6-Chloro 3-oxo 3*H*-benzo[*d*]isothiazole-2-carboxylic acid propylamide;
6-Chloro 3-oxo 3*H*-benzo[*d*]isothiazole-2-carboxylic acid butylamide;
6-Chloro 3-oxo 3*H*-benzo[*d*]isothiazole-2-carboxylic acid hexylamide;
6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid cyclohexylamide; and


8. (Currently Amended) A benzisothiazole-3(2*H*)-one compound represented by the formulae below(C1), (C2), (C3), or (C4):





9. (Currently Amended) A pharmaceutical formulation comprising a benzisothiazole-3(2H)-one compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.


10. (Currently Amended) A method of inhibiting hepatic lipase and/or endothelial lipase activity using a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I, wherein R₁-R₆ are as defined in claim 1



or a pharmaceutical acceptable salt, solvate, or prodrug thereof.

11. (Cancelled).

12. (Currently Amended) A pharmaceutical formulation containing a therapeutically effective amount of the compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R₁-R₆ are defined as in claim 1



I


formulated for the treatment and/or amelioration of the effect of elevated hepatic lipase and/or endothelial lipase activity.

13-15. (Cancelled)

16. (Previously Presented) The method of claim 10 wherein the benzothiazole-3(2H)-one compound is formulated with a pharmaceutically acceptable carrier or diluent.

17. (Cancelled)

18. (New) A method of treating hypercholesterolemia, hyperlipidemia, or atherosclerosis using a therapeutically effective amount of benzothiazole-3(2H)-one compound of formula I, wherein R₁-R₆ are as defined in claim 1



I

or a pharmaceutical acceptable salt thereof.